July 24, 2012

Improving Oral Dosage Formulations: Microencapsulation for Controlled and Immediate Release

  Cory Berkland, Ph.D., Chief Scientific Officer, Orbis Biosciences, Inc. 

Improving Oral Dosage Formulations: Microencapsulation for Controlled and Immediate Release

The need for novel drug delivery technologies is on the rise as pharmaceutical companies face steep patent expiration cliffs and a dwindling number of candidates in the R&D pipeline. Patented drug delivery technologies can enable new formulations of existing drugs thereby extending product life-cycles and protecting from generic competition while simultaneously improving drug performance including release rate, taste-masking, and format flexibility. With the oral delivery market representing the largest drug delivery route, there is significant opportunity and need for new drug delivery technologies that can specifically address this market segment.

This presentation will focus on Orbis Biosciences’ patented Precision Particle Fabrication technology and its ability to develop novel oral formulations. We will discuss how the technology can enable precise dosage control of release profiles including immediate, extended, and delayed burst for both poorly and highly water-soluble APIs while enhancing taste-masking and mouth feel. We will show how these precision microparticle drug-intermediates can be integrated into a variety of formulations including solutions, tablets, sachets, and capsules. In addition, we will discuss the key differentiating factors of the Orbis technology as it compares to current manufacturing processes. Finally, we will discuss the ability of Precision Particle Fabrication to serve as a true platform technology capable of developing formulations for oral, injectable, and topical delivery routes.

Key takeaway points:

Benefits of Orbis' Precision Particle Fabrication

Comparison of Precision Particle Fabrication melt-spray compared to spray drying and hot-melt extrusion

Precision Particle Fabrication is broadly applicable

Companies with focus on oral delivery

Positions

Cory Berkland is Co-founder and CSO of Orbis Biosciences. He is a Professor in the Department of Chemical and Petroleum Engineering and in the Department of Pharmaceutical Chemistry at The University of Kansas. He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois, Urbana-Champaign, where he co-invented and developed the Orbis technology. He is a leading expert in drug delivery and has recently been awarded the prestigious 2012 Controlled Release Society Young Investigator Award for his internationally recognized contributions in the science and technology of controlled release.

Orbis Biosciences revolutionizes the delivery, efficacy, and safety of products in the pharmaceutical, food, consumer product, and specialty chemical industries. Orbis’ technology platform, Precision Particle Fabrication, provides the ability to precisely control the release of active ingredients. This patented technology enables new products and reduces costs across these industries.